Given the fact that PDL1 is routinely upregulated in tumor cells, the triple combo medicine γδ T cell, anti-LAG3 mAb, and anti-PD1 or anti-PDL1 mAb should be a better choice. The gene discussed is LAG3; the disease is neoplasm.